Recombinant Anti-cd30 antibodies and uses thereof

a technology of cd30 and anti-cd30, which is applied in the field of recombinant anti-cd30 antibodies, can solve the problems of limiting the ability to deliver curative doses of these agents, no patient experienced tumor regression, and known anti-cd30 antibodies have not been shown to inhibit the proliferation of hd cells in culture, so as to reduce the incorporation of 3h-thymidin

Inactive Publication Date: 2008-09-04
SEATTLE GENETICS INC
View PDF3 Cites 119 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0024]In preferred embodiments, the antibodies of the invention can exert a cytostatic or cytotoxic effect on a Hodgkin's Disease cell line in the absence of effector cells (e.g., natural killer cells, neutrophils) and in a complement-independent manner.

Problems solved by technology

Yet, despite successful in vivo targeting of the malignant tumor cells, none of the patients experienced tumor regression.
One of the major limitations of immunotoxins is their inherent immunogenicity that results in the development of antibodies to the toxin molecule and neutralizes their effects (Tsutsumi et al., 2000, Proc.
Additionally, the liver toxicity and vascular leak syndrome associated with immunotoxins potentially limits the ability to deliver curative doses of these agents (Tsutsumi et al., 2000, Proc.
While some signaling mAbs to CD30, including M44, M67 and HeFi-1, have been shown to inhibit the growth of ALCL lines in vitro (Gruss et al., 1994, Blood 83:2045-2056) or in vivo (Tian et al., 1995, Cancer Res. 55:5335-5341), known anti-CD30 antibodies have not been shown to be effective in inhibiting the proliferation of HD cells in culture.
Furthermore, these unmodified mAbs possess in vivo antitumor activity against HD tumor xenografts.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Recombinant Anti-cd30 antibodies and uses thereof
  • Recombinant Anti-cd30 antibodies and uses thereof
  • Recombinant Anti-cd30 antibodies and uses thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0094]The present invention relates to proteins that bind to CD30 and exert a cytostatic or cytotoxic effect on HD cells. The invention further relates to proteins that compete with AC10 or HeFi-1 for binding to CD30 and exert a cytostatic or cytotoxic effect on HD cells. In one embodiment, the protein is an antibody. In a preferred mode of the embodiment, the antibody is AC10 or HeFi-1, most preferably a humanized or chimeric AC10 or HeFi-1.

[0095]The invention further relates to proteins encoded by and nucleotide sequences of AC10 and HeFi-1 genes. The invention further relates to fragments and other derivatives and analogs of such AC10 and HeFi-1 proteins. Nucleic acids encoding such fragments or derivatives are also within the scope of the invention. Production of the foregoing proteins, e.g., by recombinant methods, is provided.

[0096]The invention also relates to AC10 and HeFi-1 proteins and derivatives including fusion / chimeric proteins which are functionally active, i.e., whic...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
areaaaaaaaaaaa
pHaaaaaaaaaa
pHaaaaaaaaaa
Login to view more

Abstract

The present invention relates to methods and compositions for the treatment of Hodgkin's Disease, comprising administering proteins characterized by their ability to bind to CD30, or compete with monoclonal antibodies AC10 or HeFi-1 for binding to CD30, and exert a cytostatic or cytotoxic effect on Hodgkin's disease cells in the absence of effector cells or complement. Such proteins include derivatives of monoclonal antibodies AC10 and HeFi-1. The proteins of the invention can be human, humanized, or chimeric antibodies; further, they can be conjugated to cytotoxic agents such as chemotherapeutic drugs. The invention further relates to nucleic acids encoding the proteins of the invention. The invention yet further relates to a method for identifying an anti-CD30 antibody useful for the treatment or prevention of Hodgkin's Disease.

Description

[0001]This application is a continuation of U.S. patent application Ser. No. 10 / 447,257, filed May 28, 2003, which claims the benefit U.S. Provisional Application No. 60 / 400,403, filed Jul. 31, 2002, each of which is incorporated by reference herein in its entirety.1. FIELD OF THE INVENTION[0002]The present invention relates to methods and compositions for the treatment of Hodgkin's Disease, comprising administering a protein that binds to CD30. Such proteins include recombinant / variant forms of monoclonal antibodies AC10 and HeFi-1, and derivatives thereof. This invention relates to a novel class of monoclonal antibodies directed against the CD30 receptor which, in unmodified form and in the absence of effector cells and in a complement-independent manner, are capable of inhibiting the growth of CD30-expressing Hodgkin's Disease cells.2. BACKGROUND OF THE INVENTION[0003]Curative chemotherapy regimens for Hodgkin's disease represent one of the major breakthroughs in clinical oncolog...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K39/395C07K17/00A61K47/48A61P35/00C12P21/08
CPCA61K47/48246A61K47/48269C07K5/0205A61K47/4863A61K47/48569A61K47/64A61K47/642A61K47/6817A61K47/6851A61K47/6867A61P31/00A61P35/00A61P37/00A61P37/06
Inventor FRANCISCO, JOSEPH A.RISDON, GRANTWAHL, ALAN F.SIEGALL, CLAYSENTER, PETER D.DORONINA, SVETLANATOKI, BRIAN E.
Owner SEATTLE GENETICS INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products